Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Clinical Efficacy, Safety and Tolerability of a New Subcutaneous Immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the Treatment of Patients With Primary Immunodeficiencies

Introduction: Subcutaneously administered immunoglobulin (SCIG) is increasingly used to treat patients with primary immunodeficiencies (PIDs). Octanorm (marketed as cutaquig® in USA and Canada) is a new 16.5% solution of human SCIG, manufactured by a process based on that of the intravenous preparat...

Full description

Bibliographic Details
Main Authors: Roger H. Kobayashi, Sudhir Gupta, Isaac Melamed, J. Fernando Mandujano, Ai Lan Kobayashi, Bruce Ritchie, Bob Geng, Thomas Prescott Atkinson, Syed Rehman, Eva Turpel-Kantor, Jiří Litzman
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-02-01
Series:Frontiers in Immunology
Subjects:
primary immunodeficiencies
immunoglobulins
antibodies
SCIG
infections
infusion site reactions
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2019.00040/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2019.00040/full

Similar Items